Silverfin false false 30/11/2025 01/12/2024 30/11/2025 Julia Hart 01/11/2012 31 August 2026 The principal activity of the Company during the financial year was that of medical processes and treatments for skin conditions. In addition to this, the company also purchased and refurbished commercial and residential property in this period. SC435912 2025-11-30 SC435912 bus:Director1 2025-11-30 SC435912 2024-11-30 SC435912 core:CurrentFinancialInstruments 2025-11-30 SC435912 core:CurrentFinancialInstruments 2024-11-30 SC435912 core:Non-currentFinancialInstruments 2025-11-30 SC435912 core:Non-currentFinancialInstruments 2024-11-30 SC435912 core:ShareCapital 2025-11-30 SC435912 core:ShareCapital 2024-11-30 SC435912 core:RetainedEarningsAccumulatedLosses 2025-11-30 SC435912 core:RetainedEarningsAccumulatedLosses 2024-11-30 SC435912 core:LandBuildings 2024-11-30 SC435912 core:OtherPropertyPlantEquipment 2024-11-30 SC435912 core:LandBuildings 2025-11-30 SC435912 core:OtherPropertyPlantEquipment 2025-11-30 SC435912 2023-11-30 SC435912 bus:OrdinaryShareClass1 2025-11-30 SC435912 core:KeyManagementPersonnel 2025-11-30 SC435912 core:KeyManagementPersonnel 2024-11-30 SC435912 2024-12-01 2025-11-30 SC435912 bus:FilletedAccounts 2024-12-01 2025-11-30 SC435912 bus:SmallEntities 2024-12-01 2025-11-30 SC435912 bus:AuditExemptWithAccountantsReport 2024-12-01 2025-11-30 SC435912 bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 SC435912 bus:Director1 2024-12-01 2025-11-30 SC435912 core:LandBuildings core:TopRangeValue 2024-12-01 2025-11-30 SC435912 core:OtherPropertyPlantEquipment 2024-12-01 2025-11-30 SC435912 2023-12-01 2024-11-30 SC435912 core:LandBuildings 2024-12-01 2025-11-30 SC435912 core:Non-currentFinancialInstruments 2024-12-01 2025-11-30 SC435912 bus:OrdinaryShareClass1 2024-12-01 2025-11-30 SC435912 bus:OrdinaryShareClass1 2023-12-01 2024-11-30 SC435912 core:KeyManagementPersonnel 2024-12-01 2025-11-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: SC435912 (Scotland)

JULIA HART SKIN CLINIC LIMITED

UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 NOVEMBER 2025
PAGES FOR FILING WITH THE REGISTRAR

JULIA HART SKIN CLINIC LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 30 NOVEMBER 2025

Contents

JULIA HART SKIN CLINIC LIMITED

BALANCE SHEET

AS AT 30 NOVEMBER 2025
JULIA HART SKIN CLINIC LIMITED

BALANCE SHEET (continued)

AS AT 30 NOVEMBER 2025
Note 2025 2024
£ £
Restated - note 2
Fixed assets
Tangible assets 4 145,509 156,325
Investment property 5 114,386 0
259,895 156,325
Current assets
Stocks 6 222,414 5,067
Debtors 7 40,471 225,039
Cash at bank and in hand 8 59,754 30,860
322,639 260,966
Creditors: amounts falling due within one year 9 ( 406,861) ( 276,491)
Net current liabilities (84,222) (15,525)
Total assets less current liabilities 175,673 140,800
Creditors: amounts falling due after more than one year 10 ( 175,333) ( 173,612)
Provision for liabilities 11, 12 ( 6,943) 0
Net liabilities ( 6,603) ( 32,812)
Capital and reserves
Called-up share capital 13 1 1
Profit and loss account ( 6,604 ) ( 32,813 )
Total shareholder's deficit ( 6,603) ( 32,812)

For the financial year ending 30 November 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of Julia Hart Skin Clinic Limited (registered number: SC435912) were approved and authorised for issue by the Director on 31 August 2026. They were signed on its behalf by:

Julia Hart
Director
JULIA HART SKIN CLINIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 30 NOVEMBER 2025
JULIA HART SKIN CLINIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 30 NOVEMBER 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Julia Hart Skin Clinic Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in Scotland. The address of the Company's registered office is 23 - 25 Chapel Street, Dunfermline, KY12 7AW, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include investment properties and certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The director notes that the business has net liabilities of £6,603. The Company is supported through loans from the director. The director has confirmed that the loan facilities will continue to be available for at least 12 months from the date of signing these financial statements and the director will continue to support the Company. Given the current position, the director believes that any foreseeable debts can be met for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Prior year adjustment

Prior period adjustments have been recognised in the comparative period ended 30 November 2024. Information in relation to the correction and restatement of opening balances of assets and equity are included at note 2.

Turnover

Turnover represents amounts receivable for medical processes, sale of beauty products and treatments for skin conditions.

Revenue is recognised when the company has entitlement to the income in exchange for the provision of services.

Employee benefits

Short term benefits
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Statement of Income and Retained Earnings in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Balance Sheet.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Land and buildings 50 years straight line
Plant and machinery etc. 25 - 33 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Leases

The Company as lessee
Assets held under finance leases, hire purchase contracts and other similar arrangements, which confer rights and obligations similar to those attached to owned assets, are capitalised as tangible fixed assets at the fair value of the leased asset (or, if lower, the present value of the minimum lease payments as determined at the inception of the lease) and are depreciated over the shorter of the lease terms and their useful lives. The capital elements of future lease obligations are recorded as liabilities, while the interest elements are charged to the Statement of Income and Retained Earnings over the period of the leases to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

The Company as lessor
Rental income from operating leases is recognised on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight-line basis over the lease term.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Non-financial assets
At each balance sheet date, the company reviews its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Investment property

Investment property is initially recognised at cost, which includes the purchase cost and any directly attributable expenditure. Subsequently it is measured at fair value at each reporting date with changes in fair value recognised in profit or loss. Deferred taxation is provided on these gains at the rate expected to apply when the property is sold.

The fair value is determined annually by the director, on an open market value for existing use basis.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Basic financial assets
Basic financial assets, which include debtors, cash and bank balances, are measured at transaction price including transaction costs.

Basic financial liabilities
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities.

Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

2. Prior year adjustment

Prior period adjustments have been recognised in the comparative period ending 30 November 2024 to account for VAT payable to HMRC for the period covering 01 March 2022 to 30 November 2024 following a review of the activities undertaken by the company and subsequent VAT registration and to remove the corporation tax and deferred tax provisions.

As previously reported Adjustment As restated
Year ended 30 November 2024 £ £ £
Tangible Assets 166,640 (10,315) 156,325
Creditors: amounts falling due within one year (110,953) (165,538) (276,491)
Provision for liabilities (28,318) 28,318 0
Profit and loss account (114,722) 147,535 32,813

3. Employees

2025 2024
Number Number
Monthly average number of persons employed by the Company during the year, including the director 7 8

4. Tangible assets

Land and buildings Plant and machinery etc. Total
£ £ £
Cost
At 01 December 2024 0 366,057 366,057
Additions 31,779 3,050 34,829
Disposals 0 ( 18,942) ( 18,942)
At 30 November 2025 31,779 350,165 381,944
Accumulated depreciation
At 01 December 2024 0 209,732 209,732
Charge for the financial year 239 40,013 40,252
Disposals 0 ( 13,549) ( 13,549)
At 30 November 2025 239 236,196 236,435
Net book value
At 30 November 2025 31,540 113,969 145,509
At 30 November 2024 0 156,325 156,325

5. Investment property

Investment property
£
Valuation
As at 01 December 2024 0
Additions 114,386
As at 30 November 2025 114,386

Investment property represents the purchase price, professional fees and improvements incurred for investment property in this period. The director believes that this value accurately reflects the fair value of the property at the balance sheet date.

6. Stocks

2025 2024
£ £
Stocks 222,414 5,067

7. Debtors

2025 2024
£ £
Trade debtors 9,641 5,441
Corporation tax 15,632 1,512
Other debtors 15,198 218,086
40,471 225,039

8. Cash and cash equivalents

2025 2024
£ £
Cash at bank and in hand 59,754 30,860

9. Creditors: amounts falling due within one year

2025 2024
£ £
Bank loans 68,162 45,114
Trade creditors 27,500 18,803
Other taxation and social security 255,229 184,839
Obligations under finance leases and hire purchase contracts 8,810 7,453
Other creditors 47,160 20,282
406,861 276,491

Included within Bank loans are amounts advanced to the company under the Bounce Back Loan Scheme of £6,311 (2024 - £10,350), This loan is fully backed by a government guarantee.

Also Included within bank loans are amounts advanced to the company of £61,851 (2024 - £34,764) which are backed by personal guarantee by the director.

Obligations under finance leases and hire purchase contracts are secured over the related assets.

10. Creditors: amounts falling due after more than one year

2025 2024
£ £
Bank loans 140,104 129,573
Obligations under finance leases and hire purchase contracts 35,229 44,039
175,333 173,612

Included within Bank loans are amounts advanced to the company under the Bounce Back Loan Scheme of £0 (2024 - £6,311), This loan is fully backed by a government guarantee.

Also Included within bank loans are amounts advanced to the company of £140,104 (2024 - £123,262) which are backed by personal guarantee by the director.

Obligations under finance leases and hire purchase contracts are secured over the related assets.

11. Provision for liabilities

2025 2024
£ £
Deferred tax 6,943 0

12. Deferred tax

2025 2024
£ £
At the beginning of financial year 0 ( 37,871)
(Charged)/credited to the Statement of Income and Retained Earnings ( 6,943) 37,871
At the end of financial year ( 6,943) 0

13. Called-up share capital

2025 2024
£ £
Allotted, called-up and fully-paid
1 Ordinary share of £ 1.00 1 1

14. Financial commitments

Commitments

2025 2024
£ £
Total future minimum lease payments under non-cancellable operating leases 16,822 45,991

15. Related party transactions

Transactions with the entity’s director (or members of its governing body)

Amounts owed by director

2025 2024
£ £
Director's Loan Account 0 213,932

Amounts owed to director

2025 2024
£ £
Director's Loan Account 23,147 0

Advances totalling £7,126 were made to the director in this period and £248,865 was repaid. Interest of £4,660 was charged on these advances at a rate of 2.25% and 3.75%. This loan is unsecured and has no fixed terms of repayment.